Clinical Trial Update: Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating aztreonam for inhalation in cystic fibrosis patients with Pseudomonas aeruginosa infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Pseudomonas Aeruginosa Infection

Drugs mentioned

• Aztreonam for Inhalation (aztreonam)

Snippet

Sponsor: Gilead Sciences | Conditions: Cystic Fibrosis, CF | Phase 2 | Status: COMPLETED